β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Brown, James W P ^a   Buell, Alexander K ^a,c   Michaels, Thomas C T ^a   Meisl, Georg ^a   Carozza, Jacqueline ^a   Flagmeier, Patrick ^a   Vendruscolo, Michele ^a   Knowles, Tuomas P J ^a   Dobson, Christopher M ^a   Galvagnion, Céline ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; DIMYRISTOYLPHOSPHATIDYLSERINE; LIPID; PHOSPHATIDYLSERINE; PROTEIN AGGREGATE; PROTEIN BINDING;

AMINO ACID SEQUENCE; BINDING COMPETITION; CHEMISTRY; METABOLISM; PH; PROTEINOSIS; SEQUENCE ALIGNMENT; SURFACE PROPERTY;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; BETA-SYNUCLEIN; BINDING, COMPETITIVE; HYDROGEN-ION CONCENTRATION; LIPIDS; PHOSPHATIDYLSERINES; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; SEQUENCE ALIGNMENT; SURFACE PROPERTIES;

EID: 84994310304     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36010     Document Type: Article

References (47)

1. Cookson, M. R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52 (2005).
2. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048-1059 (2012).
3. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
4. Spillantini, M. G. et al. α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
5. Spillantini, M. G. & Goedert, M. The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 920, 16-27 (2000).
6. Maroteaux, L., Campanelli, J. T. & Scheller, R. H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815 (1988).
7. Clayton, D. F. & George, J. M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249-254 (1998).
8. Varkey, J. et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 285, 32486-32493 (2010).
9. Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449 (1998).
10. Rhoades, E., Ramlall, T. F., Webb, W. W. & Eliezer, D. Quantification of α-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys. J. 90, 4692-4700 (2006).
11. Ducas, V. C. & Rhoades, E. Quantifying interactions of β-synuclein and γ-synuclein with model membranes. J. Mol. Biol. 423, 528-539 (2012).
12. Wilhelm, B. G. et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Sci. 344, 1023-1028 (2014).
13. Jakes, R., Spillantini, M. G. & Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32 (1994).
14. Uversky, V. N. et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins. J. Biol. Chem. 277, 11970-11978 (2002).
15. Janowska, M. K., Wu, K.-P. & Baum, J. Unveiling transient protein-protein interactions that modulate inhibition of α-synuclein aggregation by β-synuclein, a pre-synaptic protein that co-localizes with α-synuclein. Sci. Rep. 5, 15164 (2015).
16. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. & Masliah, E. β-synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-223 (2001).
17. Hashimoto, M. et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model. Gene Ther. 11, 1713-1723 (2004).
18. Rockenstein, E. et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914, 48-56 (2001).
19. Windisch, M. et al. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory β-synuclein-derived peptides. J. Mol. Neurosci. 19, 63-69 (2002).
20. Fares, M.-B. et al. Induction of de novo alpha-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc. Natl. Acad. Sci. USA 113, E912-E921 (2016).
21. Wright, J. A., McHugh, P. C., Pan, S., Cunningham, A. & Brown, D. R. Counter-regulation of α- and β-synuclein expression at the transcriptional level. Mol. Cell. Neurosci. 57, 33-41 (2013).
22. George, J. M. The synucleins. Genome Biol. 3, reviews3002.1-reviews3002.6 (2002).
23. Buchman, V. L. et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J. Neurosci. 18, 9335-9341 (1998).
24. Bodner, C. R., Dobson, C. M. & Bax, A. Multiple tight phospholipid-binding modes of α-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 390, 775-790 (2009).
25. Fusco, G. et al. Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour. Nat. Commun. 5, 3827 (2014).
26. Bertoncini, C. W. et al. Structural characterization of the intrinsically unfolded protein β-synuclein, a natural negative regulator of α-synuclein aggregation. J. Mol. Biol. 372, 708-722 (2007).
27. Rivers, R. C. et al. Molecular determinants of the aggregation behavior of α- and β-synuclein. Protein Sci. 17, 887-898 (2008).
28. Giehm, L., Oliveira, C. L. P., Christiansen, G., Pedersen, J. S. & Otzen, D. E. SDS-induced fibrillation of α-synuclein: an alternative fibrillation pathway. J. Mol. Biol. 401, 115-133 (2010).
29. Roodveldt, C. et al. A rationally designed six-residue swap generates comparability in the aggregation behavior of α-synuclein and β-synuclein. Biochemistry 51, 8771-8778 (2012).
30. Campioni, S. et al. The presence of an air-water interface affects formation and elongation of α-synuclein fibrils. J. Am. Chem. Soc. 136, 2866-2875 (2014).
31. Vácha, R., Linse, S. & Lund, M. Surface effects on aggregation kinetics of amyloidogenic peptides. J. Am. Chem. Soc. 136, 11776-11782 (2014).
32. Galvagnion, C. et al. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229-234 (2015).
33. Grey, M., Linse, S., Nilsson, H., Brundin, P. & Sparr, E. Membrane interaction of α-synuclein in different aggregation states. J. Parkinsons. Dis. 1, 359-371 (2011).
34. Buell, A. K. et al. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc. Natl. Acad. Sci. 111, 7671-7676 (2014).
35. Sung, Y.-H. & Eliezer, D. Secondary structure and dynamics of micelle bound β- and γ-synuclein. Protein Sci. 15, 1162-1174 (2006).
36. Carulla, N. et al. Molecular recycling within amyloid fibrils. Nature 436, 554-558 (2005).
37. Arosio, P. et al. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. ACS Nano 10, 333-341 (2016).
38. Michaels, T. C. T., Buell, A. K., Terentjev, E. M. & Knowles, T. P. J. Quantitative analysis of diffusive reactions at the solid-liquid interface in finite systems. J. Phys. Chem. Lett. 5, 695-699 (2014).
39. Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T. P., Dobson, C. M., Buell, A. K. & Galvagnion, C. Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci USA. 113(37), 10328-33 (2016).
40. Wright, C. F., Teichmann, S. A., Clarke, J. & Dobson, C. M. The importance of sequence diversity in the aggregation and evolution of proteins. Nature 438, 878-881 (2005).
41. Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat. Struct. Mol. Biol. 22, 207-213 (2015).
42. Meisl, G. et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252-272 (2016).
43. Cohen, S. I. A. et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA 110, 9758-9763 (2013).
44. Hoyer, W. et al. Dependence of α-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383-393 (2002).
45. Pinotsi, D. et al. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano Lett. 14, 339-345 (2014).
46. Müller, T. et al. Particle-based Monte-Carlo simulations of steady-state mass transport at intermediate Péclet numbers. Int. J. Nonlinear Sci. Numer. Simul. 17, 175-183 (2016).
47. Buell, A. K. et al. Surface attachment of protein fibrils via covalent modification strategies. J. Phys. Chem. B 114, 10925-10938 (2010).